ArticleMolecular therapy : the journal of the American Society of Gene Therapy2022
Dual-aptamer-engineered M1 macrophage with enhanced specific targeting and checkpoint blocking for solid-tumor immunotherapy.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 28 citations in OpenAlex.
- A narrative review of barrier-matched engineering of macrophages for solid tumor immunotherapy: design logic, translational barriers and clinical outlook.Translational cancer research · 2026Review
- Targeted biologics for TNBC: Advances in nanobodies, antibodies, peptides, and aptamers.Molecular therapy. Oncology · 2026Review
- Innate immune cells in chimeric antigen receptor therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Review
- Immune cell-based therapies for solid tumors, current challenges and therapeutic advances.Cell communication and signaling : CCS · 2025Review
- Macrophage-centered therapy strategies: A promising weapon in cancer immunotherapy.Asian journal of pharmaceutical sciences · 2025Review
- Oligonucleotide-Based Modulation of Macrophage Polarization: Emerging Strategies in Immunotherapy.Immunity, inflammation and disease · 2025Review
- Glycoengineering in antigen-specific immunotherapies.Current opinion in chemical biology · 2024Review
- Promotion and Detection of Cell-Cell Interactions through a Bioorthogonal Approach.Journal of the American Chemical Society · 2024Article
- Therapeutic utility of engineered myeloid cells in the tumor microenvironment.Cancer gene therapy · 2023Review
- Aptamers Versus Vascular Endothelial Growth Factor (VEGF): A New Battle against Ovarian Cancer.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Aptamer-Based Strategies to Boost Immunotherapy in TNBC.Cancers · 2023Review
- Selection and Identification of an ssDNA Aptamer for Fibroblast Activation Protein.Molecules (Basel, Switzerland) · 2023Article
- Advancements in Macrophage-Targeted Drug Delivery for Effective Disease Management.International journal of nanomedicine · 2023Review
- Current Status and Prospects of Clinical Treatment of Osteosarcoma.Technology in cancer research & treatmentReview
Corrections and comments
- Erratum issued
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor T (CAR-T) cell therapy has faced a series of challenges and has shown very little efficacy in solid tumors to date. Although genetically engineered macrophages have achieved definite therapeutic effect in solid tumors, heterogeneous expression of engineered proteins and the potential for toxicity limit further applications. Herein, we propose a nongenetic and simple macrophage cell engineering strategy through glycan metabolic labeling and click reaction for the treatment of solid tumors. The aptamer-engineered M1 macrophage (ApEn-M1) showed enhanced active targeting ability for tumor cells in vitro and in vivo, resulting in significant cytotoxicity effects. Moreover, ApEn-M1 exhibited superior antitumor efficacy in a breast cancer xenograft mouse model and a lung metastasis mouse model of breast cancer. Interestingly, the ApEn-M1 could reprogram the immunity microenvironment by increasing T cell infiltration and enhancing T cell activity in the tumor region. Additionally, the administration of ApEn-M1 showed no obvious systemic side effects. With glycan metabolic labeling, the macrophages could be efficiently labeled with aptamers on the cell surface via click reaction without genetic alteration or cell damage. Hence, this study serves as a proof of concept for cell-surface anchor engineering and expands the range of nongenetic macrophage cell engineering strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.